128 related articles for article (PubMed ID: 2533149)
1. Review of the endocrine actions of luteinising hormone-releasing hormone analogues in premenopausal women with breast cancer.
Nicholson RI; Walker KJ; Walker RF; Read GF; Turkes A; Robertson JF; Blamey RW
Horm Res; 1989; 32 Suppl 1():198-201. PubMed ID: 2533149
[TBL] [Abstract][Full Text] [Related]
2. Zoladex: therapeutic effects in postmenopausal breast cancer.
Harris AL; Carmichael J; Cantwell BM; Dowsett M
Horm Res; 1989; 32 Suppl 1():213-6; discussion 217. PubMed ID: 2533153
[TBL] [Abstract][Full Text] [Related]
3. The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer.
Stein RC; Dowsett M; Hedley A; Gazet JC; Ford HT; Coombes RC
Br J Cancer; 1990 Oct; 62(4):679-83. PubMed ID: 2145964
[TBL] [Abstract][Full Text] [Related]
4. The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer.
Williams MR; Walker KJ; Turkes A; Blamey RW; Nicholson RI
Br J Cancer; 1986 May; 53(5):629-36. PubMed ID: 2941044
[TBL] [Abstract][Full Text] [Related]
5. Combined endocrine effects of LHRH agonist (Zoladex) and tamoxifen (Nolvadex) therapy in premenopausal women with breast cancer.
Robertson JF; Walker KJ; Nicholson RI; Blamey RW
Br J Surg; 1989 Dec; 76(12):1262-5. PubMed ID: 2532556
[TBL] [Abstract][Full Text] [Related]
6. Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survival.
Dixon AR; Robertson JF; Jackson L; Nicholson RI; Walker KJ; Blamey RW
Br J Cancer; 1990 Nov; 62(5):868-70. PubMed ID: 2147110
[TBL] [Abstract][Full Text] [Related]
7. Oestrogen pre-treatment abolishes luteinising hormone-releasing hormone testosterone stimulation.
Kreis W; Ahmann FR; Jordan VC; de Haan H; Scott M
Br J Urol; 1988 Oct; 62(4):352-4. PubMed ID: 2973364
[TBL] [Abstract][Full Text] [Related]
8. A response in advanced post-menopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist--Zoladex.
Cassano A; Astone A; Garufi C; Noviello MR; Pietrantonio F; Barone C
Cancer Lett; 1989 Nov; 48(2):123-4. PubMed ID: 2555044
[TBL] [Abstract][Full Text] [Related]
9. Zoladex: endocrine and therapeutic effects in post-menopausal breast cancer.
Harris AL; Carmichael J; Cantwell BM; Dowsett M
Br J Cancer; 1989 Jan; 59(1):97-9. PubMed ID: 2527049
[TBL] [Abstract][Full Text] [Related]
10. Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630.
Plowman PN; Nicholson RI; Walker KJ
Br J Cancer; 1986 Dec; 54(6):903-9. PubMed ID: 2948537
[TBL] [Abstract][Full Text] [Related]
11. Therapy in premenopausal women with advanced, oestrogen positive or/and progesterone positive breast cancer: surgical oophorectomy versus the LHRH analogue, Zoladex.
Robert NJ; Dalton WS; Osborne CK; Abeloff M
Horm Res; 1989; 32 Suppl 1():221-2. PubMed ID: 2533155
[TBL] [Abstract][Full Text] [Related]
12. [Therapy with gonadotropin releasing hormone agonists (zoladex) in premenopausal females with metastastic breast cancer].
Kaufmann M; Schmid H; Kiesel L; Klinga K
Geburtshilfe Frauenheilkd; 1988 Jul; 48(7):528-32. PubMed ID: 2975241
[TBL] [Abstract][Full Text] [Related]
13. Medical castration with zoladex: a conservative approach to premenopausal breast cancer.
Brambilla C; Escobedo A; Artioli R; Lechuga MJ; Motta M; Bonadonna G
Tumori; 1991 Apr; 77(2):145-50. PubMed ID: 1828640
[TBL] [Abstract][Full Text] [Related]
14. Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions.
Chrisp P; Goa KL
Drugs; 1991 Feb; 41(2):254-88. PubMed ID: 1709853
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of the luteinising hormone-releasing hormone (LHRH) analogue, Zoladex.
Furr BJ
Horm Res; 1989; 32 Suppl 1():86-92. PubMed ID: 2533160
[TBL] [Abstract][Full Text] [Related]
16. Suppression of postmenopausal ovarian steroidogenesis with the luteinizing hormone-releasing hormone agonist goserelin.
Dowsett M; Cantwell B; Lal A; Jeffcoate SL; Harris AL
J Clin Endocrinol Metab; 1988 Apr; 66(4):672-7. PubMed ID: 2964454
[TBL] [Abstract][Full Text] [Related]
17. Zoladex in advanced breast cancer.
Robertson JF; Nicholson RI; Walker KJ; Blamey RW
Horm Res; 1989; 32 Suppl 1():206-8. PubMed ID: 2533151
[TBL] [Abstract][Full Text] [Related]
18. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.
Klijn JG; Blamey RW; Boccardo F; Tominaga T; Duchateau L; Sylvester R;
J Clin Oncol; 2001 Jan; 19(2):343-53. PubMed ID: 11208825
[TBL] [Abstract][Full Text] [Related]
19. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
Ahmann FR; Citrin DL; deHaan HA; Guinan P; Jordan VC; Kreis W; Scott M; Trump DL
J Clin Oncol; 1987 Jun; 5(6):912-7. PubMed ID: 2953870
[TBL] [Abstract][Full Text] [Related]
20. Treatment of pre-menopausal advanced breast cancer with goserelin--a long-acting luteinizing hormone releasing hormone agonist.
Brambilla C; Escobedo A; Artioli R; Lechuga MJ; Motta M
Anticancer Drugs; 1992 Feb; 3(1):3-8. PubMed ID: 1535804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
